RU95104885A - 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция - Google Patents

1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция

Info

Publication number
RU95104885A
RU95104885A RU95104885/14A RU95104885A RU95104885A RU 95104885 A RU95104885 A RU 95104885A RU 95104885/14 A RU95104885/14 A RU 95104885/14A RU 95104885 A RU95104885 A RU 95104885A RU 95104885 A RU95104885 A RU 95104885A
Authority
RU
Russia
Prior art keywords
indole
glyoxylamides
fatty acids
pharmaceutical composition
mediated fatty
Prior art date
Application number
RU95104885/14A
Other languages
English (en)
Other versions
RU2128169C1 (ru
Inventor
Джеймс Бач Николас
Us]
Дилейн Диллард Роберт
Элизабет Драхейм Сюзн
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU95104885A publication Critical patent/RU95104885A/ru
Application granted granted Critical
Publication of RU2128169C1 publication Critical patent/RU2128169C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

В изобретении предлагается класс новых 1Н-индол-З-глиоксиламидов, а также использование таких производных индола для ингибирования SРLА-медиируемого выделения жирных кислот для лечения таких состояний, как септический шок.

Claims (1)

  1. В изобретении предлагается класс новых 1Н-индол-З-глиоксиламидов, а также использование таких производных индола для ингибирования SРLА-медиируемого выделения жирных кислот для лечения таких состояний, как септический шок.
RU95104885/04A 1994-04-01 1995-03-31 Iн-индол-3-глиоксиламиды, ингибирующие spla2-медиируемое выделение жирных кислот, фармацевтическая композиция RU2128169C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22191694A 1994-04-01 1994-04-01
US08/221.916 1994-04-01
US08/221916 1994-04-01

Publications (2)

Publication Number Publication Date
RU95104885A true RU95104885A (ru) 1997-04-27
RU2128169C1 RU2128169C1 (ru) 1999-03-27

Family

ID=22829963

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95104885/04A RU2128169C1 (ru) 1994-04-01 1995-03-31 Iн-индол-3-глиоксиламиды, ингибирующие spla2-медиируемое выделение жирных кислот, фармацевтическая композиция

Country Status (29)

Country Link
US (6) US5654326A (ru)
EP (5) EP1197484A2 (ru)
JP (1) JP3109974B2 (ru)
KR (1) KR100368707B1 (ru)
CN (1) CN1067054C (ru)
AT (2) ATE540923T1 (ru)
AU (1) AU688458B2 (ru)
BR (1) BR9501404A (ru)
CA (1) CA2146097C (ru)
CO (1) CO4370099A1 (ru)
CZ (1) CZ82295A3 (ru)
DE (1) DE69527322T2 (ru)
DK (2) DK0675110T3 (ru)
ES (2) ES2377223T3 (ru)
FI (1) FI114793B (ru)
HU (1) HUT72048A (ru)
IL (1) IL113210A (ru)
MX (1) MX9501608A (ru)
MY (1) MY112897A (ru)
NO (1) NO304186B1 (ru)
NZ (1) NZ270848A (ru)
PE (1) PE18696A1 (ru)
PL (1) PL180523B1 (ru)
PT (1) PT675110E (ru)
RU (1) RU2128169C1 (ru)
SI (1) SI0675110T1 (ru)
TW (1) TW383302B (ru)
UA (1) UA47387C2 (ru)
ZA (1) ZA952693B (ru)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY112897A (en) * 1994-04-01 2001-10-31 Lilly Co Eli Ih-indole-3-glyoxylamide spla2 inhibitors
JPH08193074A (ja) * 1994-11-18 1996-07-30 Nippon Bayeragrochem Kk 除草性１−シクロプロピルテトラゾリノン類
US6043264A (en) * 1995-01-06 2000-03-28 Toray Industries, Inc. Benzene-condensed heterocyclic derivatives and their uses
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
CA2308443A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
JP2001520991A (ja) * 1997-10-27 2001-11-06 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２阻害剤のＮ，Ｎ−ジエチルグリコールアミドエステルプロドラッグ
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) * 1997-11-14 2000-10-04 Eli Lilly And Company Treatment for alzheimer's disease
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease
NZ506329A (en) * 1998-02-25 2004-01-30 Inst Genetics Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1058547B1 (en) * 1998-03-03 2005-11-23 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
CN1303384A (zh) 1998-03-31 2001-07-11 盐野义制药株式会社 吡咯并[1,2－a]吡嗪sPLA2抑制剂
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
US6407261B1 (en) 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
EP1071661A4 (en) * 1998-04-17 2001-08-22 Lilly Co Eli METHOD FOR PRODUCING 4-HYDROXYINDOL, INDAZOL AND CARBAZOL COMPOUNDS
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE69921314T2 (de) * 1998-05-01 2006-02-09 Eli Lilly And Co., Indianapolis INHIBITORISCHE ESTER FÜR sPLA 2
HUP0102243A2 (hu) * 1998-05-01 2001-10-28 Eli Lilly And Co. sPLA2-inhibitor vegyületek betegség kezelésére
US6472389B1 (en) 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect
EP1100492B1 (en) * 1998-08-03 2006-05-24 Eli Lilly & Company INDOLE sPLA2 INHIBITORS
AU5331499A (en) * 1998-08-03 2000-02-28 Eli Lilly And Company Indole spla2 inhibitors
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DZ2771A1 (fr) * 1998-10-09 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
CA2346334A1 (en) 1998-10-14 2000-04-20 Shionogi & Co., Ltd. Composition for treating or preventing ischemia reperfusion injury
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
WO2000037022A2 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2000037358A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company NOVEL sPLA2 INHIBITORS
AU1928800A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Substituted tricyclics
US6380397B1 (en) 1999-04-15 2002-04-30 Eli Lilly And Company Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6703385B1 (en) 1999-07-19 2004-03-09 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
WO2001009130A1 (fr) 1999-08-02 2001-02-08 Shionogi & Co., Ltd. COMPOSES TRICYCLIQUES A ACTIVITES INHIBANT sPLA¿2?
JP4623483B2 (ja) 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
JP2003509491A (ja) * 1999-09-20 2003-03-11 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
AU1304801A (en) 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
AU2252201A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
AU2050001A (en) * 1999-12-16 2001-06-25 Eli Lilly And Company Synthesis of indole-containing spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1259260A1 (en) * 2000-01-06 2002-11-27 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
US20030096854A1 (en) * 2002-06-12 2003-05-22 Ho-Shen Lin Substituted tricyclics
EP1248769A2 (en) * 2000-01-07 2002-10-16 Eli Lilly And Company Carbazole derivatives as inhibitors of spla2
EP1265607A2 (en) * 2000-03-09 2002-12-18 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS
BR0002188A (pt) * 2000-03-30 2001-11-13 Brasil Compressores Sa Processo de formação do pacote de lâminasmetálicas de estator de motor elétrico e pacotede lâminas metálicas
WO2001081306A2 (en) * 2000-04-19 2001-11-01 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
WO2002000255A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre le cancer
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
AU2001280461A1 (en) * 2000-08-04 2002-02-18 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
EP1358156B1 (en) 2000-12-18 2007-02-21 Eli Lilly And Company Benz(g) indoles and their use as spla2 inhibitors
TWI314457B (ru) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
US6903104B2 (en) 2001-12-06 2005-06-07 National Health Research Institutes Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
MX2008005664A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Compuestos de indol que tienen sustituyentes c4-acidos y uso de los mismos como inhibidores de fosfolipasa a2.
JP2009517341A (ja) * 2005-11-03 2009-04-30 イリプサ， インコーポレイテッド Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
MX2008005662A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Compuestos de azaindol y uso de los mismos como inhibidores de la fosfolipasa a2.
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN102015656A (zh) * 2008-04-28 2011-04-13 旭化成制药株式会社 苯丙酸衍生物及其用途
WO2010081022A1 (en) * 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN101838232B (zh) * 2009-07-07 2012-02-22 爱斯医药科技(南京)有限公司 Varespladib的制备方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10894035B2 (en) * 2015-08-31 2021-01-19 Diaccurate Use of indole compounds to stimulate the immune system

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825734A (en) 1955-04-11 1958-03-04 Upjohn Co Reduction of carbonylic radicals in indolyl-3 compounds
US2825743A (en) 1955-08-30 1958-03-04 Celanese Corp Catalytic hydrogenation of unsaturated aldehydes and ketones
US3242163A (en) * 1961-03-13 1966-03-22 Merck & Co Inc Indolyl aliphatic acids
US3259622A (en) * 1962-09-07 1966-07-05 Merck & Co Inc 1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
GB1089071A (en) 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
NL287416A (ru) 1964-04-25
US3449363A (en) 1966-12-22 1969-06-10 American Cyanamid Co 3-substituted 4-trifluoromethyl indoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
US3691194A (en) * 1970-07-30 1972-09-12 Little Inc A 3-indole-glyoxamides
US3686213A (en) 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
US4397850A (en) 1981-10-07 1983-08-09 Sandoz, Inc. Isoxazolyl indolamines
US4552876A (en) * 1984-07-09 1985-11-12 Usv Pharmaceutical Corp. Bisbenzoxazines and pharmaceutical use
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ234883A (en) * 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5192770A (en) * 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
MY112897A (en) 1994-04-01 2001-10-31 Lilly Co Eli Ih-indole-3-glyoxylamide spla2 inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
SK77598A3 (en) 1995-12-14 1999-01-11 Merck & Co Inc Nonpeptide derivatives, pharmaceutical composition containing them and their use
WO1997021704A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2001520991A (ja) * 1997-10-27 2001-11-06 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２阻害剤のＮ，Ｎ−ジエチルグリコールアミドエステルプロドラッグ

Also Published As

Publication number Publication date
DK1950200T3 (da) 2012-04-10
RU2128169C1 (ru) 1999-03-27
ATE220394T1 (de) 2002-07-15
SI0675110T1 (en) 2002-12-31
TW383302B (en) 2000-03-01
ES2377223T3 (es) 2012-03-23
NZ270848A (en) 1997-05-26
MY112897A (en) 2001-10-31
PL307951A1 (en) 1995-10-02
CN1114310A (zh) 1996-01-03
EP1950200B1 (en) 2012-01-11
US6175021B1 (en) 2001-01-16
FI114793B (fi) 2004-12-31
UA47387C2 (ru) 2002-07-15
EP1197484A2 (en) 2002-04-17
ZA952693B (en) 1996-09-30
FI951553A0 (fi) 1995-03-31
NO951252D0 (no) 1995-03-31
DE69527322T2 (de) 2003-02-27
AU1621795A (en) 1995-10-12
ATE540923T1 (de) 2012-01-15
AU688458B2 (en) 1998-03-12
EP0675110B1 (en) 2002-07-10
US6433001B1 (en) 2002-08-13
EP0675110A1 (en) 1995-10-04
IL113210A0 (en) 1995-06-29
HUT72048A (en) 1996-03-28
PL180523B1 (pl) 2001-02-28
BR9501404A (pt) 1996-03-05
PT675110E (pt) 2002-11-29
US5919943A (en) 1999-07-06
US5733923A (en) 1998-03-31
JP3109974B2 (ja) 2000-11-20
FI951553A (fi) 1995-10-02
ES2179088T3 (es) 2003-01-16
US5654326A (en) 1997-08-05
CA2146097C (en) 2000-03-21
CA2146097A1 (en) 1995-10-02
CO4370099A1 (es) 1996-10-07
KR100368707B1 (ko) 2003-06-02
EP1081135A2 (en) 2001-03-07
HU9500957D0 (en) 1995-05-29
NO951252L (no) 1995-10-02
DK0675110T3 (da) 2002-10-07
US5919810A (en) 1999-07-06
JPH07285933A (ja) 1995-10-31
MX9501608A (es) 1997-02-28
IL113210A (en) 2001-01-28
EP2341045A1 (en) 2011-07-06
CN1067054C (zh) 2001-06-13
EP1081135A3 (en) 2003-11-05
EP1950200A1 (en) 2008-07-30
CZ82295A3 (en) 1995-12-13
PE18696A1 (es) 1996-05-30
DE69527322D1 (de) 2002-08-14
KR950032117A (ko) 1995-12-20
NO304186B1 (no) 1998-11-09

Similar Documents

Publication Publication Date Title
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
CO4920242A1 (es) Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
RU95112484A (ru) Производные 2,3,4,5-тетрагидро-1,4-бензотиазепинов, фармацевтическая композиция, способ лечения неврологических расстройств, припадков, способ защиты нервной системы, способ получения, использование
RU94012930A (ru) Новые 1-н-индол-3-ацетамиды как ингибиторы spla2 и фармацевтическая композиция на их основе
CO4900033A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen .
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
MX9702865A (es) Agentes estrogenicos.
DE69612003T2 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
BR0109011A (pt) Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica
RU94046306A (ru) Производные индолокарбазолимида, смесь их изомеров или отдельные изомеры и их соли и фармацевтическая композиция с активностью, ингибирующей протеинкиназу с или киназу легкой миозиновой цепи или подавляющей иммунные реакции
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94036448A (ru) Производные галантамина и фармацевтическая композиция
EA199900301A2 (ru) Замещенные трициклические соединения
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
RU94036761A (ru) Производные галантамина и фармацевтическая композиция
EA200101077A1 (ru) Композиция для профилактики или лечения слабоумия, включающая производное гидроксикоричной кислоты или экстракт растения рода angelicae, содержащий его
CO4900045A1 (es) Compuestos inhibidores de metaloproteasas espirociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94044454A (ru) Ингибитор аутоимунных заболеваний
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20040401